Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Trial Profile

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Durvalumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms DURATION
  • Most Recent Events

    • 08 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 31 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top